A global pharmaceutical giant, leaders in the care of diabetes, obesity, and other chronic diseases in the life sciences sector, had the vision to be a Top 5 player in clinical trials and drug development time-to-market by 2025. As a first step, they needed to understand the best-in-class market standards today and where they stand in terms of operational processes, technology platforms/infrastructure, and digital capabilities within life sciences.
Bringing a new drug to market involves a complex web of processes cutting across stakeholder groups in the life sciences industry. Friction between sub-processes typically costs the life sciences industry tens of billions every year. Delayed time-to-market results in escalating costs and the risk of missing market opportunities.
